{"id":"W4389617190","doi":"10.1038/s41467-023-44071-8","title":"Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial","year":2023,"lang":"en","type":"erratum","venue":"Nature Communications","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Carboplatin; Paclitaxel; Durvalumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Triple negative; Randomized controlled trial; Internal medicine; Cancer; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00882777,0.002275306,0.002197096,0.002825767,0.002195649,0.003573109,0.00345507,0.007337375,0.03588278],"category_scores_gemma":[0.08256649,0.001297563,0.002581285,0.002224117,0.0015474,0.001509377,0.001227892,0.01404985,0.02390551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00385306,"about_ca_system_score_gemma":0.00702039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01309284,"about_ca_topic_score_gemma":0.01604991,"domain_scores_codex":[0.9938788,0.00149714,0.001312127,0.0008431564,0.002050044,0.0004187626],"domain_scores_gemma":[0.9600755,0.01575607,0.002277459,0.002029919,0.01823357,0.001627435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000495797,0.000004390058,0.00002625105,0.0001057149,0.00001253859,0.00006988506,0.000008814921,0.00001918918,0.00001700447,0.0001810219,0.9971908,0.002314816],"study_design_scores_gemma":[0.0004147223,0.00004452697,0.0007039395,0.0009405648,0.0001818199,0.0004831062,0.00005274805,0.000302517,0.000395633,0.001422986,0.9950072,0.00005011623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.00006407144,0.0006934589,0.0003601495,0.04566562,0.9508076,0.00003587958,0.0009255069,0.000161437,0.001286331],"genre_scores_gemma":[0.007538112,0.007506612,0.004320824,0.2407695,0.6069641,0.0005981774,0.002611339,0.001075248,0.128616],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.03588278,"threshold_uncertainty_score":0.1200398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0273204916225204,"score_gpt":0.3623504589377628,"score_spread":0.3350299673152424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}